Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline
Merck is bulking up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.
Arm jumps 16% as company expects revenue windfall from new chip, a ‘significant shift’
Arm said it expects its new chip to generate six times more revenue in 2031 than the $4 billion it made in 2025.
Treasury yields tumble as Trump talks up Iran ceasefire plan
U.S. Treasury yields ticked lower on Wednesday amid hopes of a potential peace plan in the Middle East.
Private credit’s ‘zero-loss fantasy’ is coming to an end as defaults and fund exits rise
Private credit is expected to see a surge in defaults as investors continue to pull money from the sector.
Pop Mart shares plunge over 22% as concerns over sustainability of Labubu sales dwarf stellar results
the Beijing-based toy maker posted annual revenue of 37.1 billion yuan ($5.4 billion) for 2025, up 185% from a year earlier, just shy of LSEG estimates of 38 billion yuan.
What comes after Labubu? Inside Pop Mart’s next grow play
Pop Mart is betting on films, theme parks and global expansion to turn Labubu into a lasting franchise, even as the initial craze fades.
South Korea braces for ‘worst-case scenarios’ as Iran oil shock deepens
South Korean Prime Minister Kim Min-seok warned the government must prepare for “worst-case scenarios” stemming from the Middle East conflict.
Don’t be fooled by the UK’s pre-war inflation print — a ‘brutal’ surge could be coming
The U.K. inflation rate stood firm at 3% in February, according to the latest figures from the Office for National Statistics (ONS).
CNBC Daily Open: Plan for peace or a wish list?
Sentiment turns positive as the U.S. claims to be in active negotiations with Iran, while details emerge of a potential path to peace.
